ECF Transporter Inhibitors for Multi-Vitamin Uptake Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial treatments lack effective targets for Gram-positive bacteria such as Streptococcus pneumoniae and Enterococcus species, as existing antibiotics face challenges with resistance and limited mechanisms of action.
Innovation Solution
Development of novel inhibitors targeting the Energy Coupling Factor (ECF) transporters, specifically group-II ECF transporters, which are unique to bacteria and essential for vitamin uptake, allowing simultaneous blockage of multiple vitamins with a single inhibitor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics are used to treat Gram-positive bacteria, then bacterial infections can be treated, but antibiotic resistance develops and mechanisms of action become limited
Solution Approach 1:
The invention segments the ECF transporter system into three distinct components (ECF-A nucleotide-binding domain, ECF-T transmembrane domain, and S-component substrate-binding protein), allowing targeted inhibition at the ECF-ATP interface. This segmentation enables development of novel antimicrobial mechanisms that specifically disrupt vitamin uptake without affecting other bacterial processes, thereby overcoming antibiotic resistance while maintaining treatment effectiveness.
2Adaptability or versatility
If multiple S-components are targeted individually, then specific vitamin uptake can be inhibited, but device complexity and number of compounds required increase
Solution Approach 1:
The invention creates a universal inhibitor platform that targets the conserved ECF-ATP binding interface, which is shared across all ECF transporters regardless of their specific S-component. A single compound design can therefore inhibit multiple different ECF transporters (such as FolT for folate, ThiT for thiamine, and B12T for cobalamin) by binding to the common ATP-binding region, achieving multi-vitamin inhibition without requiring separate compounds for each transporter.
Data Source
AI summary
The present invention relates to novel inhibitors of the Energy Coupling Factor (ECF) Transporters. These compounds of general formula (Ia) or (Ib) are useful in the treatment of bacterial infections, especially caused by Streptococcus pneumoniae, Enterococcus faecium, Enterococcus faecalis.